21326246|phase ii study|C0282460|start=0|end=14|PROC
21326246|s-1|C0393005|start=18|end=21|PROC
21326246|combined|C0205195|start=22|end=30|CONC
21326246|therapy|C0039798^C0087111|start=51|end=58|PROC^CONC
21326246|metastatic|C1522484^C0036525|start=77|end=87|CONC
21326246|biliary tract cancer|C0750952|start=88|end=108|DISO
21326246|cyp2a6|C1413868^C1706116|start=127|end=133|GENE
21326246|polymorphism|C0032529^C1882417|start=134|end=146|PHYS^CONC
21326246|pharmacokinetics|C0031328^C0031327|start=150|end=166|PHYS^CONC
21326246|clinical|C1611832^C1555900^C1608518^C3272565^C0205210|start=171|end=179|CONC
21326246|activity|C0026606^C0441655^C0205177|start=180|end=188|ACTI^CONC
21326246|background|C1706907|start=190|end=200|CONC
21326246|advanced|C0205179|start=202|end=210|CONC
21326246|biliary cancer|C0750952|start=211|end=225|DISO
21326246|treated with|C0332293^C1522326|start=235|end=247|PROC^CONC
21326246|based|C1705938^C1527178|start=265|end=270|CONC
21326246|chemotherapy|C0392920^C3665472^C0013217|start=271|end=283|PROC^CONC
21326246|study|C0947630^C2603343^C0557651^C0008972^C1705923^C1880229|start=293|end=298|PROC^OBJC^CONC
21326246|evaluated|C0220825|start=303|end=312|PROC
21326246|efficacy|C1280519^C1707887|start=317|end=325|PROC^CONC
21326246|tolerability|C3274448|start=330|end=342|PROC
21326246|combination|C1947911^C0205195|start=348|end=359|OBJC^CONC
21326246|s-1|C0393005|start=363|end=366|PROC
21326246|oral|C1527415^C0226896^C0442027|start=371|end=375|CONC^ANAT
21326246|metastatic|C1522484^C0036525|start=435|end=445|CONC
21326246|biliary cancer|C0750952|start=446|end=460|DISO
21326246|methods|C0025664^C0449851^C0025663|start=462|end=469|CONC
21326246|histologically|C0205462|start=485|end=499|CONC
21326246|confirmed|C0521093^C0750484|start=500|end=509|CONC
21326246|metastatic|C1522484^C0036525|start=510|end=520|CONC
21326246|biliary cancer|C0750952|start=521|end=535|DISO
21326246|no history of|C0332122|start=540|end=553|CONC
21326246|radiotherapy|C0243005^C0034619^C1522449|start=554|end=566|OCCU^PROC^CONC
21326246|chemotherapy|C0392920^C3665472^C0013217|start=570|end=582|PROC^CONC
21326246|administered|C1521801|start=614|end=626|CONC
21326246|followed by|C0332283|start=657|end=668|CONC
21326246|administration|C1533734^C0001554|start=676|end=690|PROC^ACTI
21326246|oral|C1527415^C0226896^C0442027|start=694|end=698|CONC^ANAT
21326246|s-1|C0393005|start=699|end=702|PROC
21326246|twice daily|C0585361|start=716|end=727|CONC
21326246|subsequent|C0332282|start=736|end=746|CONC
21326246|rest|C0035253^C1622890^C1419346|start=753|end=757|GENE^PHYS^ACTI
21326246|period|C1561960^C2347804^C1948053^C0025344^C0439531|start=758|end=764|PROC^PHYS^CONC
21326246|days|C0439228|start=774|end=778|CONC
21326246|pharmacokinetic|C0201734|start=780|end=795|PROC
21326246|analysis|C1524024^C0936012^C0002778|start=796|end=804|PROC^CONC
21326246|s-1|C0393005|start=808|end=811|PROC
21326246|performed|C0884358|start=816|end=825|CONC
21326246|cycle|C1511572|start=829|end=834|CONC
21326246|cyp2a6|C1413868^C1706116|start=866|end=872|GENE
21326246|polymorphisms|C0032529|start=873|end=886|PHYS
21326246|pharmacokinetic|C0201734|start=926|end=941|PROC
21326246|clinical|C1611832^C1555900^C1608518^C3272565^C0205210|start=946|end=954|CONC
21326246|compared|C1707455|start=966|end=974|ACTI
21326246|cyp2a6|C1413868^C1706116|start=992|end=998|GENE
21326246|genotype|C1285573^C0017431|start=999|end=1007|PROC^PHYS
21326246|total|C0439810|start=1021|end=1026|CONC
21326246|evaluated|C0220825|start=1045|end=1054|PROC
21326246|received|C1514756|start=1060|end=1068|CONC
21326246|median|C0876920^C2347635^C2939193^C0549183^C2348144|start=1071|end=1077|CONC
21326246|cycles|C1511572|start=1086|end=1092|CONC
21326246|response rate|C0237629|start=1106|end=1119|CONC
21326246|median|C0876920^C2347635^C2939193^C0549183^C2348144|start=1131|end=1137|CONC
21326246|progression|C0242656^C0449258|start=1138|end=1149|DISO^CONC
21326246|free|C1996904^C1880497^C0332296|start=1150|end=1154|CONC
21326246|survival|C0038952^C0220921|start=1167|end=1175|ACTI^CONC
21326246|months|C0439231|start=1192|end=1198|CONC
21326246|common|C0205214^C3245511^C1522138|start=1223|end=1229|CONC
21326246|grade 3|C0687697^C1883548^C0450094|start=1245|end=1252|CONC
21326246|toxicity|C0600688^C0040539|start=1262|end=1270|DISO^CONC
21326246|neutropenia|C0023530^C0027947|start=1275|end=1286|DISO
21326246|non|C1518422|start=1300|end=1303|CONC
21326246|grade 3|C0687697^C1883548^C0450094|start=1318|end=1325|CONC
21326246|toxicities|C0600688|start=1335|end=1345|DISO
21326246|included|C0332257|start=1346|end=1354|CONC
21326246|anorexia|C0003123|start=1355|end=1363|DISO
21326246|nausea|C0027497^C1963179|start=1371|end=1377|DISO
21326246|asthenia|C0004093|start=1385|end=1393|DISO
21326246|vomiting|C0042963|start=1401|end=1409|DISO
21326246|diarrhoea|C0011991|start=1421|end=1430|DISO
21326246|biotransformation|C0220798^C0005576|start=1437|end=1454|PHYS^CONC
21326246|s-1|C0393005|start=1458|end=1461|PROC
21326246|auc|C0376690|start=1463|end=1466|CONC
21326246|auc|C0376690|start=1493|end=1496|CONC
21326246|fold|C0332462^C1880834|start=1526|end=1530|PHEN^CONC
21326246|group|C1552516^C1561557^C1705428^C0441833|start=1552|end=1557|ORGA^CONC
21326246|groups|C1552839^C0441833|start=1577|end=1583|CONC
21326246|confidence interval|C0009667|start=1589|end=1608|CONC
21326246|diarrhoea|C0011991|start=1621|end=1630|DISO
21326246|neutropenia|C0023530^C0027947|start=1643|end=1654|DISO
21326246|clinical efficacy|C3850123|start=1670|end=1687|CONC
21326246|response rate|C0237629|start=1689|end=1702|CONC
21326246|pfs|C0242792|start=1713|end=1716|CONC
21326246|associated with|C0332281|start=1750|end=1765|CONC
21326246|cyp2a6|C1413868^C1706116|start=1766|end=1772|GENE
21326246|genotype|C1285573^C0017431|start=1773|end=1781|PROC^PHYS
21326246|exposure|C0274281^C0332157^C0728853^C1704625|start=1811|end=1819|DISO^PHEN^PHYS^CONC
21326246|conclusion|C1707478|start=1821|end=1831|CONC
21326246|combination|C1947911^C0205195|start=1837|end=1848|OBJC^CONC
21326246|s-1|C0393005|start=1852|end=1855|PROC
21326246|active|C1553875^C1561510^C1706449^C1561511^C1561512^C1547419^C1561513^C1561507^C1561508^C1561509^C0205177^C2347179|start=1886|end=1892|PROC^CONC
21326246|metastatic|C1522484^C0036525|start=1929|end=1939|CONC
21326246|biliary cancer|C0750952|start=1940|end=1954|DISO
21326246|therapeutic|C0039796^C1547427^C0302350|start=1982|end=1993|PROC^CONC
21326246|modality|C0695347^C1547664|start=1994|end=2002|PROC^CONC
21326246|cyp2a6|C1413868^C1706116|start=2004|end=2010|GENE
21326246|genotypes|C0017431|start=2011|end=2020|PHYS
21326246|associated with|C0332281|start=2025|end=2040|CONC
21326246|biotransformation|C0220798^C0005576|start=2060|end=2077|PHYS^CONC
21326246|s-1|C0393005|start=2081|end=2084|PROC
21326246|impact|C0726639^C1825598|start=2099|end=2105|GENE^OBJC
21326246|cyp2a6|C1413868^C1706116|start=2113|end=2119|GENE
21326246|polymorphism|C0032529^C1882417|start=2120|end=2132|PHYS^CONC
21326246|variations|C0205419|start=2136|end=2146|CONC
21326246|clinical efficacy|C3850123|start=2150|end=2167|CONC
21326246|toxicity|C0600688^C0040539|start=2171|end=2179|DISO^CONC
21326246|evaluation|C1550157^C1261322^C0220825|start=2197|end=2207|PROC^CONC
